In patients with stage IV melanoma, the high frequency of CD14+ CD16− HLA-DRhi monocytes in peripheral blood samples before anti-PD-1 immunotherapy was a strong predictor of PFS and OS in response to PD-1 immunotherapy [44]. Here, PDCD1 is linked to melanoma.